Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Neratinib Boosts PFS in Pretreated Advanced HER2-positive Breast Cancer

quotesThe results of the NALA trial were presented earlier and led to the approval of the combination of n…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

quotesWhile a "complete response" is great for our patients, the Complete Response Letter was less auspici…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

New Study Finds COVID-19 Substantially Reduced Cancer Screenings, Diagnosis, and Treatments in 2020

quotesThis is a very important but scary study we conducted. Cancer screenings are still down and we have …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

Community Oncology Alliance (COA) Payment Reform Brief Details 35 Oncology Payment Models Underway or Planned Across Country

quotesCOA leaders clearly are among the elite as experts nationally in the understanding and design of pay…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. …quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

CMS Coverage Draft Shuns 1st-to-Market Colorectal Cancer Blood Test, Outlines Path For Exact, Guardant

quotesBlood-based cancer screening appears now to be the “holy Grail” (pun intended) of early cancer d…quotes

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Neratinib Boosts PFS in Pretreated Advanced HER2-positive Breast Cancer

quotesThe results of the NALA trial were presented earlier and led to the approval of the combination of n…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Targeted Inhibitor of Mutated KRAS Gene Shows Promise in Early Trial for Lung, Bowel, and Other Solid Tumors

quotesThese new data with adagrasib look modestly superior for response rate compared to sotorasib, and wh…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

quotesWhile a "complete response" is great for our patients, the Complete Response Letter was less auspici…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Comments

Studies Back Salvage RT After Prostatectomy

quotesMultiple randomized trials comparing adjuvant RT after radical prostatectomy (with undetectable PSA)…quotes

member-photo

Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Stephen M. Schleicher, M.D., MBA

Community Oncology,
Medical Oncologist,
OneOncology

Comments

Divergent Findings With Paclitaxel and Nab-Paclitaxel in TNBC

quotesThe finding that atezolizumab is beneficial only with Abraxane and NOT paclitaxel not only has impor…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

New Study Finds COVID-19 Substantially Reduced Cancer Screenings, Diagnosis, and Treatments in 2020

quotesThis is a very important but scary study we conducted. Cancer screenings are still down and we have …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

Association of Community Cancer Centers Statement on Rise of Cancer Mortality and Advanced Cancer Rates in 2020

quotesThis report is extremely disturbing. Interesting in that it also appears the same day a Wall Street …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

Community Oncology Alliance (COA) Payment Reform Brief Details 35 Oncology Payment Models Underway or Planned Across Country

quotesCOA leaders clearly are among the elite as experts nationally in the understanding and design of pay…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Targeted Inhibitor of Mutated KRAS Gene Shows Promise in Early Trial for Lung, Bowel, and Other Solid Tumors

quotesThese new data with adagrasib look modestly superior for response rate compared to sotorasib, and wh…quotes

member-photo

Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

CMS Coverage Draft Shuns 1st-to-Market Colorectal Cancer Blood Test, Outlines Path For Exact, Guardant

quotesBlood-based cancer screening appears now to be the “holy Grail” (pun intended) of early cancer d…quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

Association of Community Cancer Centers Statement on Rise of Cancer Mortality and Advanced Cancer Rates in 2020

quotesThis report is extremely disturbing. Interesting in that it also appears the same day a Wall Street …quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Comments

Studies Back Salvage RT After Prostatectomy

quotesMultiple randomized trials comparing adjuvant RT after radical prostatectomy (with undetectable PSA)…quotes